The emergence of cefiderocol resistance in 
        Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Nicholas Teran; Stephanie L Egge; Kady Phe; Rodrigo P Baptista; Vincent H Tam; William R Miller

doi:10.1128/aac.01009-23

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Nicholas Teran, Stephanie L Egge, Kady Phe, Rodrigo P Baptista, Vincent H Tam, William R Miller

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

Original language	English (US)
Pages (from-to)	e0100923
Journal	Antimicrobial Agents and Chemotherapy
Volume	68
Issue number	1
Early online date	Dec 8 2023
DOIs	https://doi.org/10.1128/aac.01009-23
State	Published - Jan 10 2024

Keywords

cefiderocol
Gram-negative bacteria
Pseudomonas aeruginosa
siderophores
gram-negative bacteria
Gram-Negative Bacteria
Humans
Drug Resistance, Multiple, Bacterial/genetics
Cefiderocol
Monobactams/pharmacology
Anti-Bacterial Agents/pharmacology
Microbial Sensitivity Tests
Cephalosporins/pharmacology
Pseudomonas Infections/drug therapy

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Divisions

Infectious Disease

Access to Document

10.1128/aac.01009-23

Cite this

@article{37990d0907594a49a6121119a6ea6c69,

title = "The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.",

abstract = "Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance. ",

keywords = "cefiderocol, Gram-negative bacteria, Pseudomonas aeruginosa, siderophores, gram-negative bacteria, Gram-Negative Bacteria, Humans, Drug Resistance, Multiple, Bacterial/genetics, Cefiderocol, Monobactams/pharmacology, Anti-Bacterial Agents/pharmacology, Microbial Sensitivity Tests, Cephalosporins/pharmacology, Pseudomonas Infections/drug therapy",

author = "Nicholas Teran and Egge, \{Stephanie L\} and Kady Phe and Baptista, \{Rodrigo P\} and Tam, \{Vincent H\} and Miller, \{William R\}",

note = "Publisher Copyright: {\textcopyright} 2023 American Society for Microbiology.",

year = "2024",

month = jan,

day = "10",

doi = "10.1128/aac.01009-23",

language = "English (US)",

volume = "68",

pages = "e0100923",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

TY - JOUR

T1 - The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

AU - Teran, Nicholas

AU - Egge, Stephanie L

AU - Phe, Kady

AU - Baptista, Rodrigo P

AU - Tam, Vincent H

AU - Miller, William R

PY - 2024/1/10

Y1 - 2024/1/10

N2 - Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

AB - Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with mutations in the PirA and PiuA/D TonB-dependent receptor pathways. Here, we report a clinical case of cefiderocol-resistant P. aeruginosa that emerged in a patient during treatment. This resistance was associated with mutations not previously reported, suggesting potential novel pathways to cefiderocol resistance.

KW - cefiderocol

KW - Gram-negative bacteria

KW - Pseudomonas aeruginosa

KW - siderophores

KW - gram-negative bacteria

KW - Gram-Negative Bacteria

KW - Humans

KW - Drug Resistance, Multiple, Bacterial/genetics

KW - Cefiderocol

KW - Monobactams/pharmacology

KW - Anti-Bacterial Agents/pharmacology

KW - Microbial Sensitivity Tests

KW - Cephalosporins/pharmacology

KW - Pseudomonas Infections/drug therapy

UR - https://www.scopus.com/pages/publications/85182091068

UR - https://www.scopus.com/inward/citedby.url?scp=85182091068&partnerID=8YFLogxK

U2 - 10.1128/aac.01009-23

DO - 10.1128/aac.01009-23

M3 - Article

C2 - 38063509

SN - 0066-4804

VL - 68

SP - e0100923

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

ER -